✨ Regulatory Notices
NEW ZEALAND GAZETTE, No. 49 — 11 MAY 2017
I, Ray Smith, Chief Executive, Department of Corrections, hereby give notice that on 8 May 2017 I made rules, under section 80ZT of the Sentencing Act 2002, section 74A of the Parole Act 2002, and section 103C of the Public Safety (Public Protection Orders) Act 2014, prescribing the testing procedures and monitoring devices that may be used for testing for alcohol and other drugs.
These rules come into force on 16 May 2017.
The rules may be downloaded from the Department of Corrections website: www.corrections.govt.nz.
The rules will be available for public inspection free of charge at the reception of the Department of Corrections’ National Office at 44–52 The Terrace, Wellington.
Dated at Wellington this 8th day of May 2017.
RAY SMITH, Chief Executive, Department of Corrections.
2017-go2250
Notice of Application to Vary the Conditions of a Registered Trade Name Product
(Notice No. MPI 756)
Maree Zinzley, Manager Approvals Operations of the Ministry for Primary Industries (MPI), acting under delegated authority from the Director-General of MPI, gives notice, under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 ("Act"), that the following variation application has been made to a registered trade name product under section 9(2) of the Act:
Trade Names:
- Vetmedin 1.25mg Capsules for Dogs
- Vetmedin 2.5mg Capsules for Dogs
- Vetmedin 5mg Capsules for Dogs
References:
- A009130-16
- A7867-20
- A7868-20
Active Ingredients and Concentrations:
- Pimobendan 1.25mg per capsule
- Pimobendan 2.5mg per capsule
- Pimobendan 5mg per capsule
Formulation Type: Capsule
Current Claims:
The treatment of canine congestive heart failure (CHF) originating from dilated cardiomyopathy (DMC) or valvular insufficiency (mitral and/or tricuspid regurgitation).
The treatment of preclinical DCM in large breed dogs. When used in cases of preclinical DCM in large breed dogs, pimobendan significantly prolonged the time to the onset of CHF or sudden death, and also resulted in prolongation of the time to death due to all causes.
Doberman Pinscher dogs with preclinical DCM treated with pimobendan also demonstrated a significant reduction in Left Ventricular Internal Diameter in both systole and diastole (LVIDs/d) in response to therapy.
Proposed New Claims (changes in bold):
The treatment of canine congestive heart failure (CHF) originating from dilated cardiomyopathy (DMC) or valvular insufficiency (mitral and/or tricuspid regurgitation).
The treatment of preclinical DCM in large breed dogs. When used in cases of preclinical DCM in large breed dogs, pimobendan significantly prolonged the time to the onset of CHF or sudden death, and also resulted in prolongation of the time to death due to all causes.
Doberman Pinscher dogs with preclinical DCM treated with pimobendan also demonstrated a significant reduction in Left Ventricular Internal Diameter in both systole and diastole (LVIDs/d) in response to therapy.
For the treatment of dogs with evidence of increased heart size secondary to asymptomatic
Next Page →
NZ Gazette 2017, No 49
✨ LLM interpretation of page content
⚖️
Department of Corrections Chief Executive Rules for Alcohol and Other Drug Testing
(continued from previous page)
⚖️ Justice & Law Enforcement8 May 2017
Corrections, Alcohol testing, Drug testing, Rules, Sentencing Act 2002, Parole Act 2002, Public Safety (Public Protection Orders) Act 2014
- Ray Smith, Chief Executive, Department of Corrections
🌾 Notice of Application to Vary the Conditions of a Registered Trade Name Product
🌾 Primary Industries & ResourcesTrade name variation, Veterinary medicine, Pimobendan, Vetmedin, MPI, Agricultural Compounds and Veterinary Medicines Act 1997
- Maree Zinzley, Manager Approvals Operations, Ministry for Primary Industries